Alumis (ALMS) Liabilities and Shareholders Equity (2023 - 2026)
Alumis (ALMS) posted quarterly Liabilities and Shareholders Equity of $411.9 million for Q4 2025, up 20.81% year-over-year from $341.0 million in Q4 2024, and down 15.59% quarter-over-quarter from $488.0 million in Q3 2025.
Analysis
Alumis (ALMS) Liabilities and Shareholders Equity (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $411.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity rose 20.81% year-over-year to $411.9 million; the TTM figure through Dec 2025 stood at $1.8 billion (up 73.96% YoY), while the FY2025 annual figure was $411.9 million, up 20.81% from the prior year.
- Liabilities and Shareholders Equity fell to $411.9 million in Q4 2025 per ALMS's latest filing, from $488.0 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $610.9 million in Q2 2025 and bottomed at $89.6 million in Q4 2023.
- Historically, Liabilities and Shareholders Equity has averaged $360.1 million across 3 years, with a median of $376.5 million in 2024.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 280.52% — and 2025, when it grew 18.29%.
- Alumis' Liabilities and Shareholders Equity stood at $89.6 million in 2023, then soared by 280.52% to $341.0 million in 2024, then grew by 20.81% to $411.9 million in 2025.
- Business Quant data shows ALMS's Liabilities and Shareholders Equity at $411.9 million in Q4 2025, $488.0 million in Q3 2025, and $610.9 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Alumis | 1.42 Bn | 919.00 Mn | - | 560.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 560.62 Mn |
| Dec 31, 2025 | 411.94 Mn |
| Sep 30, 2025 | 488.01 Mn |
| Jun 30, 2025 | 610.93 Mn |
| Mar 31, 2025 | 261.30 Mn |
| Dec 31, 2024 | 340.99 Mn |
| Sep 30, 2024 | 412.56 Mn |
| Jun 30, 2024 | 265.18 Mn |
| Dec 31, 2023 | 89.61 Mn |